Cited by 361SARS-CoV-2 detection and testingSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Open access

GeurtsvanKessel, Corine H., Okba, Nisreen M. A., Igloi, Zsofia, Bogers, Susanne, Embregts, Carmen W. E., Laksono, Brigitta M., Leijten, Lonneke, Rokx, Casper, Rijnders, Bart, Rahamat-Langendoen, Janette, van den Akker, Johannes P. C., van Kampen, Jeroen J. A., van der Eijk, Annemiek A., van Binnendijk, Rob S., Haagmans, Bart, Koopmans, Marion·2020·Nature Communications

DOI 10.1038/s41467-020-17317-yPMC PMC7338506

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41467-020-17317-y

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Performance of commercial assays for the detection of SARS-CoV-2-specific antibodies. Correlation of SARS-CoV-2 neutralizing antibody titers tested by a plaque reduction neutralization assay (PRNT50) to antibodies measured by selected assays. (a) Wantai Ig total ELISA, (b) Wantai IgM ELISA, (c) Euroimmun IgG ELISA, (d) Euroimmun IgA ELISA, (e) DiaSorin Liaison XL IgG chemiluminescence immunoassay, (f) Cellex IgM/IgG, (g) InTec IgM/IgG, (h) Orient gene/Healgen IgM/IgG. Turquoise dots indicate patient specimen collected ≤7 days post onset of symptoms (dps), magenta dots indicate samples collected from 8–14 dps, gray dots indicate specimen collected more than 14 dps. Dotted lines indicate the cut-off for positivity of each assay, as indicated by the manufacturer: Wantai ELISAs, OD ratio > 1; Euroimmun ELISAs, OD ratio > 1.1; DiaSorin Liaison IgG >15 AU/ml. OD: optical density, AU: arbitrary units, r: correlation coefficient. (i) Percentages of specificities and sensitivities of the various platforms tested. The arrow bar indicates the upper and lower limit of the 95% CI. Source data are provided as a Source Data file.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Self-citation
Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
Flaxman, S. R., Mishra, S., Gandy, A., Unwin, H. J. T., Mellan, T. A., Coupland, H., Whittaker, C., Zhu, H., Berah, T., Eaton, J. W., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77731 · Cited by 632
Evaluation of nine commercial SARS-CoV-2 immunoassaysPreprint
Lassaunière, R., Frische, A., Harboe, Z. B., Nielsen, A. C. Y., Fomsgaard, A., Krogfelt, K. A., & Jørgensen, C. S. (2020) · medRxiv · doi:10.1101/2020.04.09.20056325 · Cited by 319
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227
Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward
Bryant, J. E., Azman, A. S., Ferrari, M. J., Arnold, B. F., Boni, M. F., Boum, Y., Hayford, K. T., Luquero, F. J., Mina, M. J., Rodríguez-Barraquer, I., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc6347 · Cited by 142
Herd immunity is not a realistic exit strategy during a COVID-19 outbreakPreprint
Slot, E., Hogema, B. M., Reusken, C. B. E. M., Reimerink, J. H. J., Molier, M., Karregat, J. H. M., IJlst, J., Novotny, V. M. J., van Lier, R. A. W., & Zaaijer, H. L. (2020) · Research Square · doi:10.21203/rs.3.rs-25862/v1 · Cited by 55

Show all 10 references

Sorted by citations

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans
Munnink, B. B. O., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Münger, E., Molenkamp, R., van der Spek, A. N., Tolsma, P., Rietveld, A., Brouwer, M., et al. (2020) · Science · doi:10.1126/science.abe5901 · Cited by 1,116
Self-citation
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
van Kampen, J. J. A., van de Vijver, D. A. M. C., Fraaij, P. L. A., Haagmans, B. L., Lamers, M. M., Okba, N., van den Akker, J. P. C., Endeman, H., Gommers, D. A. M. P. J., Cornelissen, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20568-4 · Cited by 838
Self-citation
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B. (2021) · Science · doi:10.1126/science.abe6959 · Cited by 775
SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients
Geers, D., Shamier, M. C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N. N., Schmitz, K. S., Rijsbergen, L. C., van Osch, J. A. T., Dijkhuizen, E., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj1750 · Cited by 529
Self-citation
COVID-19: Discovery, diagnostics and drug development
Asselah, T., Durantel, D., Pasmant, É., Lau, G. K. K., & Schinazi, R. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.031 · Cited by 478
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Ainsworth, M. A., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E. J., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30634-4 · Cited by 341
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C. H., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef, J. E., Dofferhoff, A. S. M., Ludwig, I., Koster, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23469-2 · Cited by 351
Self-citation
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
Muruato, A. E., Fontes-Garfias, C. R., Ren, P., Garcia-Blanco, M. A., Menachery, V. D., Xie, X., & Shi, P.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17892-0 · Cited by 319
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., Santis, M. D., Acosta‐Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 319
Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients
Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J., Clearly, S., Furrie, E., Greig, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa659 · Cited by 308
COVID-19 Antibody Tests and Their Limitations
Liu, G., & Rusling, J. F. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02621 · Cited by 226
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
Figueiredo‐Campos, P., Blankenhaus, B., Mota, C., Gomes, A., Serrano, M., Ariotti, S., da Costa, C. J. M., Nunes‐Cabaço, H., Mendes, A. M., Gaspar, P., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048970 · Cited by 211
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B. A. G., Wormann, B. J., Turajlic, S., & von Lilienfeld‐Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 211
Self-citation
Antibody tests for identification of current and past infection with SARS-CoV-2
Fox, T., Geppert, J., Dinnes, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P. N., Wickramasinghe, D., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652.pub2 · Cited by 205
A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice
de Alwis, R., Gan, E. S., Chen, S., Leong, Y. S., Tan, H. C., Zhang, S. L., Yau, C., Low, J. G. H., Kalimuddin, S., Matsuda, D., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.001 · Cited by 191
“Similar protocols have been published previously for SARS-CoV-2.”
Influential
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
Kalimuddin, S., Tham, C. Y. L., Qui, M., de Alwis, R., Sim, J. X. Y., Lim, J. M. E., Tan, H.-C., Syenina, A., Zhang, S. L.-X., Bert, N. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.003 · Cited by 182
Review of Current Advances in Serologic Testing for COVID-19
Freire, A. P. E., Akgun, Y., Mana, A. F. A., Tjendra, Y., Millan, N. C., Gomez-Fernandez, C. R., & Cray, C. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa112 · Cited by 170
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172
SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence
den Hartog, G., Schepp, R. M., Kuijer, M., GeurtsvanKessel, C., van Beek, J., Rots, N., Koopmans, M. P. G., van der Klis, F. R. M., & van Binnendijk, R. S. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa479 · Cited by 137
Self-citation
Validation of a commercially available SARS-CoV-2 serological immunoassay
Meyer, B., Torriani, G., Yerly, S., Mazza, L., Calame, A., Arm‐Vernez, I., Zimmer, G., Agoritsas, T., Stirnemann, J., Spechbach, H., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.024 · Cited by 157
Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy
Poletti, P., Tirani, M., Cereda, D., Trentini, F., Guzzetta, G., Sabatino, G., Marziano, V., Castrofino, A., Grosso, F. M., Castillo, G. D., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.1085 · Cited by 155
Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
Padoan, A., Bonfante, F., Pagliari, M., Bortolami, A., Negrini, D., Zuin, S., Bozzato, D., Cosma, C., Sciacovelli, L., & Plebani, M. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103101 · Cited by 145
How to interpret and use COVID-19 serology and immunology tests
Ong, D. S. Y., Fragkou, P. C., Schweitzer, V. A., Chemaly, R. F., Moschopoulos, C. D., & Skevaki, C. L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.001 · Cited by 144
Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories
Harritshøj, L. H., Gybel‐Brask, M., Afzal, S., Kamstrup, P. R., Jørgensen, C. S., Thomsen, M. K., Hilsted, L. M., Friis-Hansen, L. J., Szecsi, P. B., Pedersen, L., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02596-20 · Cited by 133
Laboratory testing for the diagnosis of COVID-19
Lai, C. K. C., & Lam, W. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.069 · Cited by 140
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
Eyre, D. W., Lumley, S. F., Wei, J., Cox, S., James, T., Justice, A., Jesuthasan, G., O'Donnell, D., Howarth, A., Hatch, S. B., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.041 · Cited by 131
Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
Meyer, B., Reimerink, J. H. J., Torriani, G., Brouwer, F., Godeke, G.-J., Yerly, S., Hoogerwerf, M. N., Vuilleumier, N., Kaiser, L., Eckerle, I., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1835448 · Cited by 131
Recent advances in nanomaterials based biosensors for point of care (PoC) diagnosis of Covid-19 – A minireview
Annasamy, G., Kumar, N. A., & Anand, S. (2021) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2021.116205 · Cited by 131
Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects
Rasmi, Y., Li, X., Khan, J., Özer, T., & Choi, J. R. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03377-6 · Cited by 132
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Geers, D., Schmitz, K. S., Garrido, H. M. G., Koopmans, M., Dalm, V. A. S. H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116747 · Cited by 127
Self-citation
A comparative review of immunoassays for COVID-19 detection
Mohit, E., Rostami, Z., & Vahidi, H. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1908886 · Cited by 120
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays
Tang, M. S., Case, J. B., Franks, C. E., Chen, R. E., Anderson, N. W., Henderson, J. P., Diamond, M., Gronowski, A. M., & Farnsworth, C. W. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa211 · Cited by 113
Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset
Wynberg, E., van Willigen, H. D. G., Dijkstra, M., Boyd, A. C., Kootstra, N. A., van den Aardweg, J. G., van Gils, M. J., Matser, A. A., de Wit, M. R., Leenstra, T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab759 · Cited by 105
Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis
Gong, F., Wei, H.-X., Li, Q., Liu, L., & Li, B. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.682405 · Cited by 109
Development strategies of conducting polymer-based electrochemical biosensors for virus biomarkers: Potential for rapid COVID-19 detection
Tran, V. V., Tran, N. H. T., Hwang, H. S., & Chang, M. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113192 · Cited by 103
Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study
Zhang, Z., Bi, Q., Fang, S., Wei, L., Wang, X., He, J., Wu, Y., Liu, X., Gao, W., Zhang, R., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30200-7 · Cited by 95
De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV‑2 Spike Protein
Pomplun, S. J., Jbara, M., Quartararo, A. J., Zhang, G., Brown, J. S., Lee, Y., Ye, X., Hanna, S., & Pentelute, B. L. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c01309 · Cited by 89
A CRISPR-based ultrasensitive assay detects attomolar concentrations of SARS-CoV-2 antibodies in clinical samples
Tang, Y., Song, T., Gao, L., Yin, S., Ma, M., Tan, Y., Wu, L., Yang, Y., Wang, Y., Lin, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32371-4 · Cited by 88
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
Simón, D., Taşçılar, K., Krönke, G., Kleyer, A., Zaiss, M. M., Heppt, F., Meder, C. H., Atreya, R. N., Klenske, E., Dietrich, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17703-6 · Cited by 84
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma
Fenwick, C. W., Turelli, P., Pellaton, C., Farina, A., Campos, J., Raclot, C., Pojer, F., Cagno, V., Gonseth, S., D’Acremont, V., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8452 · Cited by 87
SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies–a narrative review
Kumar, R., Yeni, C. M., Utami, N. A., Masand, R., Asrani, R. K., Patel, S. K., Kumar, A., Yatoo, M. I., Tiwari, R., Natesan, S., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.04.005 · Cited by 82
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19
Vogelzang, E. H., Loeff, F. C., Derksen, N. I. L., Kruithof, S., Heer, P. O., van Mierlo, G. J., Linty, F., Mok, J. Y., van Esch, W. J. E., de Bruin, S., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000767 · Cited by 78
The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature
Machado, B. A. S., Hodel, K. V. S., Júnior, V. G. B., Soares, M. B. P., & Badaró, R. J. D. S. (2020) · Viruses · doi:10.3390/v13010040 · Cited by 77
Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta‐analysis
Mekonnen, D. S., Mengist, H. M., Derbie, A., Nibret, E., Munshea, A., He, H., Li, B., & Jin, T. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2181 · Cited by 80
Humoral immune mechanisms involved in protective and pathological immunity during COVID-19
Widjaja, G., Jalil, A. T., Rahman, H. S., Abdelbasset, W. K., Bokov, D. O., Suksatan, W., Ghaebi, M., Marofi, F., Navashenaq, J. G., Jadidi‐Niaragh, F., et al. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.06.011 · Cited by 75
Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test
Bal, A., Pozzetto, B., Trabaud, M., Escuret, V., Rabilloud, M., Langlois, C., Paul, A., Guibert, N., d’Aubarede, C., Massardier-Pilonchery, A., et al. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa336 · Cited by 74
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
Nielsen, S. S. F., Vibholm, L. K., Monrad, I., Olesen, R., Frattari, G. S., Pahus, M. H., Højen, J. F., Gunst, J. D., Erikstrup, C., Holleufer, A., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103410 · Cited by 76
Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study
Luijten, L. W. G., Leonhard, S. E., van der Eijk, A. A., Doets, A. Y., Appeltshauser, L., Arends, S., Attarian, S., Benedetti, L., Briani, C., Casasnovas, C., et al. (2021) · Brain · doi:10.1093/brain/awab279 · Cited by 87
Limited specificity of commercially available SARS‐CoV‐2 IgG ELISAs in serum samples of African origin
Emmerich, P., Murawski, C., Ehmen, C., von Possel, R., Pekarek, N., Oestereich, L., Duraffour, S., Pahlmann, M., Struck, N. S., Eibach, D., et al. (2021) · Tropical Medicine & International Health · doi:10.1111/tmi.13569 · Cited by 72
Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World
Augustine, R., Das, S., Hasan, A., Abhilash, S., Salam, S. A., Augustine, P., Dalvi, Y. B., Varghese, R., Primavera, R., Yassine, H. M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103372 · Cited by 71
Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections
Wang, P. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2020.113919 · Cited by 70
Serologic Screening of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Cats and Dogs during First Coronavirus Disease Wave, the Netherlands
Zhao, S., Schuurman, N., Li, W., Wang, C., Smit, L. A. M., Broens, E. M., Wagenaar, J. A., van Kuppeveld, F. J. M., Bosch, B., & Egberink, H. F. (2021) · Emerging infectious diseases · doi:10.3201/eid2705.204055 · Cited by 68
Seroprevalence of and Risk Factors Associated With SARS-CoV-2 Infection in Health Care Workers During the Early COVID-19 Pandemic in Italy
Poletti, P., Tirani, M., Cereda, D., Guzzetta, G., Trentini, F., Marziano, V., Toso, C., Piatti, A., Piccarreta, R., Melegaro, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.15699 · Cited by 69
Development of a rapid and sensitive quantum dot nanobead-based double-antigen sandwich lateral flow immunoassay and its clinical performance for the detection of SARS-CoV-2 total antibodies
Zhou, Y., Chen, Y., Liu, W., Fang, H., Li, X., Hou, L., Liu, Y., Lai, W., Huang, X., & Xiong, Y. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.130139 · Cited by 68
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
van Leeuwen, L. P. M., GeurtsvanKessel, C. H., Ellerbroek, P. M., de Bree, G. J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F. L., Gorp, E. C. M. V., de Wilt, F., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.002 · Cited by 67
Self-citation
Pulling-Force Spinning Top for Serum Separation Combined with Paper-Based Microfluidic Devices in COVID-19 ELISA Diagnosis
Gong, F., Wei, H.-X., Qi, J., Ma, H., Liu, L., Weng, J., Zheng, X., Li, Q., Zhao, D., Fang, H., et al. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00773 · Cited by 69
Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
Dzimianski, J. V., Lorig‐Roach, N., O’Rourke, S. M., Alexander, D. L., Kimmey, J. M., & DuBois, R. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-78895-x · Cited by 65
The Prevalence of Antibodies to SARS-CoV-2 Among Blood Donors in China
Chang, L., Hou, W., Zhao, L., Zhang, Y., Wang, Y., Wu, L., Xu, T., Wang, L., Wang, J., Ma, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-021-21503-x · Cited by 68
One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents
Zhang, J., Lin, H., Ye, B., Zhao, M. J., Zhan, J., Dong, S., Guo, Y., Zhao, Y., Li, M., Liu, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab884 · Cited by 69
Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation
Calvo-Lozano, O., Sierra, M., Soler, M., Estévez, M. ‐., Chiscano‐Camón, L., Ruiz-Sanmartín, A., Ruiz‐Rodríguez, J. C., Ferrer, R., González‐López, J. J., Esperalba, J., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03850 · Cited by 70
Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma
Maor‬‏, ‪., Cohen, D., Paran, N., Israely, T., Ezra, V., Axelrod, O., Shinar, E., Izak, M., Rahav, G., Rahimi‐Levene, N., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100525 · Cited by 64
B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19
Wildner, N. H., Ahmadi, P., Schulte, S., Brauneck, F., Kohsar, M., Lütgehetmann, M., Beisel, C., Addo, M. M., Haag, F., & Wiesch, J. S. Z. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5cova0620-370rr · Cited by 64
A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies
Yao, Z., Drecun, L., Aboualizadeh, F., Kim, S. J., Li, Z., Wood, H., Valcourt, E. J., Manguiat, K., Plenderleith, S. W., Yip, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22102-6 · Cited by 65
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
Gundlapalli, A. V., Salerno, R. M., Brooks, J. T., Averhoff, F. M., Petersen, L. R., McDonald, L. C., Iademarco, M. F., Response, C. C.-1., Carroll, Y. I., Gorwitz, R. J., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa555 · Cited by 63
Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting
Müller, L., Ostermann, P. N., Walker, A., Wienemann, T., Mertens, A., Adams, O., Andrée, M., Hauka, S., Lübke, N., Keitel, V., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04169-7 · Cited by 59
SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021
Mandolo, J., Msefula, J., Henrion, M. Y. R., Brown, C., Moyo, B., Samon, A., Moyo-Gwete, T., Makhado, Z., Ayres, F., Motlou, T., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02187-y · Cited by 61
Group Testing for SARS-CoV-2 Allows for Up to 10-Fold Efficiency Increase Across Realistic Scenarios and Testing Strategies
Verdun, C. M., Fuchs, T., Harár, P., Elbrächter, D., Fischer, D. S., Berner, J., Grohs, P., Theis, F. J., & Krahmer, F. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.583377 · Cited by 61
Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages
Pérez‐López, B., & Mir, M. (2020) · Talanta · doi:10.1016/j.talanta.2020.121898 · Cited by 60
Probability of symptoms and critical disease after SARS-CoV-2 infectionPreprint
Poletti, P., Tirani, M., Cereda, D., Trentini, F., Guzzetta, G., Sabatino, G., Marziano, V., Castrofino, A., Grosso, F., Del Castillo, G., et al. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2006.08471 · Cited by 80
Innovative FO-SPR Label-free Strategy for Detecting Anti-RBD Antibodies in COVID-19 Patient Serum and Whole Blood
Qu, J.-H., Leirs, K., Maes, W., Imbrechts, M., Callewaert, N., Lagrou, K., Geukens, N., Lammertyn, J., & Spasić, D. (2022) · ACS Sensors · doi:10.1021/acssensors.1c02215 · Cited by 59
Humoral Immune Response to SARS-CoV-2
Herroelen, P. H., Martens, G. A., Smet, D. D., Swaerts, K., & Decavele, A.-S. C. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa140 · Cited by 57
Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody
Trabaud, M., Icard, V., Milon, M.-P., Bal, A., Lina, B., & Escuret, V. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104613 · Cited by 58
High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris
Anna, F., Goyard, S., Lalanne, A. I., Névo, F., Gransagne, M., Souque, P., Louis, D., Gillon, V., Turbiez, I., Bidard, F., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202049058 · Cited by 58
COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa
Bright, B., Babalola, C. P., Sam-Agudu, N. A., Onyeaghala, A. A., Olatunji, A., Aduh, U., Sobande, P. O., Crowell, T. A., Tebeje, Y. K., Phillip, S., et al. (2021) · Globalization and Health · doi:10.1186/s12992-021-00668-6 · Cited by 59
High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya
Ngere, I., Dawa, J., Hunsperger, E., Otieno, N. A., Masika, M., Amoth, P., Makayotto, L., Nasimiyu, C., Gunn, B. M., Nyawanda, B. O., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.08.062 · Cited by 57
Recent Progress in Nanotechnology for COVID-19 Prevention, Diagnostics and Treatment
Rasmi, Y., Sahbani, S. K., Nemati, M., & Choi, J. R. (2021) · Nanomaterials · doi:10.3390/nano11071788 · Cited by 60
Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients
Li, Y., Lai, D., Lei, Q., Xu, Z., Wang, F., Hou, H., Chen, L., Wu, J., Ren, Y., Ma, M., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00612-5 · Cited by 53
Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers
Padoan, A., Bonfante, F., Cosma, C., Chiara, C. D., Sciacovelli, L., Pagliari, M., Bortolami, A., Costenaro, P., Musso, G., Basso, D., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0313 · Cited by 57
Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for COVID-19: A Longitudinal Study of Respiratory, Physical, and Psychological Outcomes
Hellemons, M. E., Huijts, S., Bek, L. M., Berentschot, J. C., Nakshbandi, G., Schurink, C. A. M., Vlake, J. H., van Genderen, M. E., van Bommel, J., Gommers, D., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-340oc · Cited by 56
Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody
Liu, K., Han, Y.-J., Wu, G.-H., Huang, K.-Y. A., & Huang, P.-N. (2022) · Viruses · doi:10.3390/v14071560 · Cited by 57
Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
Majiya, H., Aliyu‐Paiko, M., Balogu, T. V., Musa, D. A., Salihu, I. M., Kawu, A. A., Bashir, I. Y., Sani, A. R., John, B., Muhammad, A. T., et al. (2023) · JMIRx Med · doi:10.2196/29587 · Cited by 56
Microfluidic devices for the detection of viruses: aspects of emergency fabrication during the COVID-19 pandemic and other outbreaks
Berkenbrock, J. A., Grecco-Machado, R., & Achenbach, S. C. (2020) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2020.0398 · Cited by 54
Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
Raadsen, M. P., Gharbharan, A., Jordans, C. C. E., Mykytyn, A. Z., Lamers, M. M., van den Doel, P. B., Endeman, H., van den Akker, J. P. C., GeurtsvanKessel, C. H., Koopmans, M., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01168-3 · Cited by 55
Self-citation
Unique Severe COVID-19 Placental Signature Independent of Severity of Clinical Maternal Symptoms
Husen, M., van der Meeren, L. E., Verdijk, R. M., Fraaij, P. L. A., van der Eijk, A. A., Koopmans, M., Freeman, L. M., Bogers, H., Trietsch, M. D., Reiss, I. K. M., et al. (2021) · Viruses · doi:10.3390/v13081670 · Cited by 51
Self-citation
Virological and Immunological Features of SARS-CoV-2 Infected Children Developing Specific and Neutralizing Antibodies
Cotugno, N., Ruggiero, A., Bonfante, F., Petrara, M. R., Zicari, S., Pascucci, G. R., Zangari, P., Ioris, M. A. D., Santilli, V., Manno, E. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.108852 · Cited by 48
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
Muecksch, F., Wise, H. M., Templeton, K. E., Batchelor, B., Squires, M., McCance, K., JARVIS, L. M., Malloy, K., Furrie, E., Richardson, C., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00090-8 · Cited by 48
Sensitive Detection of Total Anti-Spike Antibodies and Isotype Switching in Asymptomatic and Symptomatic COVID-19 Patients
Goh, Y. S., Chavatte, J., Jieling, A. L., Lee, B. T. K., Hor, P. X., Amrun, S. N., Lee, C. Y., Chee, R. S., Wang, B., Lee, C. Y., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100193 · Cited by 48
Frequency Shift Surface-Enhanced Raman Spectroscopy Sensing: An Ultrasensitive Multiplex Assay for Biomarkers in Human Health
Zhu, W., Hutchison, J. A., Dong, M., & Li, M. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00393 · Cited by 48
SARS‐CoV ‐2 antibody persistence in COVID ‐19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance
Germanio, C. D., Simmons, G., Kelly, K. K., Martinelli, R., Darst, O., Azimpouran, M., Stone, M., Hazegh, K. E., Grebe, E., Zhang, S., et al. (2021) · Transfusion · doi:10.1111/trf.16555 · Cited by 44
Diagnostic performance of commercially available COVID-19 serology tests in Brazil
Cota, G., Freire, M. L., de Souza, C. S., Pedras, M. J., Saliba, J. W., de Faria, V. C. S., Alves, L. L., Rabello, A., & de Avelar, D. M. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.008 · Cited by 48
Differences in SARS-CoV-2 infections during the first and second wave of SARS-CoV-2 between six ethnic groups in Amsterdam, the Netherlands: A population-based longitudinal serological study
Coyer, L., Boyd, A. C., Schinkel, J., Agyemang, C. O., Galenkamp, H., Koopman, A. D. M., Leenstra, T., van Duijnhoven, Y. T. H. P., van Charante, E. P. M., van den Born, B. H., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100284 · Cited by 46
N protein‐based ultrasensitive SARS‐CoV‐2 antibody detection in seconds via 3D nanoprinted, microarchitected array electrodes
Ali, M. A., Hu, C., Zhang, F., Jahan, S., Yuan, B., Saleh, M. S., Gao, S., & Panat, R. P. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27591 · Cited by 49
SPEEDS: A portable serological testing platform for rapid electrochemical detection of SARS-CoV-2 antibodies
Peng, R., Pan, Y., Li, Z., Qin, Z., Rini, J. M., & Liu, X. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113762 · Cited by 45
Comparison of different serological assays for SARS-CoV-2 in real life
Brochot, É., Demey, B., Handala, L., François, C., Duverlie, G., & Castelain, S. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104569 · Cited by 43
On-chip integrated graphene aptasensor with portable readout for fast and label-free COVID-19 detection in virus transport medium
Xu, L., Ramadan, S., Rosa, B. M. G., Zhang, Y., Yin, T., Torres, E., Shaforost, O., Panagiotopoulos, A., Li, B., Kerherve, G., et al. (2022) · Sensors & Diagnostics · doi:10.1039/d2sd00076h · Cited by 43
Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays
Semmler, G., Traugott, M. T., Graninger, M., Hoepler, W., Seitz, T., Kelani, H., Karolyi, M., Pawelka, E., Cruz, S. A. D. L., Puchhammer‐Stöckl, E., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02890-20 · Cited by 41
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
Valdivia, A., Torres, I., Latorre, V., Francés‐Gómez, C., Albert, E., Gozalbo‐Rovira, R., Alcaráz, M. J., Buesa, J., Rodríguez‐Díaz, J., Geller, R., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04128-8 · Cited by 40
Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
Embregts, C. W. E., Verstrepen, B. E., Langermans, J. A. M., Böszörményi, K. P., Sikkema, R. S., de Vries, R. D., Hoffmann, D., Wernike, K., Smit, L. A. M., Zhao, S., et al. (2021) · One Health · doi:10.1016/j.onehlt.2021.100313 · Cited by 35
Self-citation

Authors: GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., van den Akker, J. P. C., van Kampen, J. J. A., van der Eijk, A. A., van Binnendijk, R. S., Haagmans, B., & Koopmans, M.
Affiliations: Erasmus MC (NL)
Radboud University Medical Center (NL)
Corresponding author: GeurtsvanKessel, Corine H.
ORCID: GeurtsvanKessel, Corine H.
Okba, Nisreen M. A.
Igloi, Zsofia
Bogers, Susanne
Embregts, Carmen W. E.
Laksono, Brigitta M.
Rokx, Casper
Rijnders, Bart
Rahamat-Langendoen, Janette
Haagmans, Bart
Koopmans, Marion
Venue: Nature Communications
Publisher: Springer Science and Business Media LLC
Published: 2020-07-06
Volume: 11
Issue: 1
Pages: 3436-3436
ISSN: 2041-1723 (ISSN-L)
DOI: 10.1038/s41467-020-17317-y
PMC: PMC7338506
OpenAlex: W3039328844
Cited by: 361
References: 10
Citations by year: 2026: 5 · 2025: 9 · 2024: 15 · 2023: 33 · 2022: 66 · 2021: 165 · 2020: 68
FWCI: 10.89
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Communications (publishedVersion, cc-by)
medRxiv (acceptedVersion)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Radboud Repository (Radboud University) (submittedVersion)
Rivm Repository (Netherlands National Institute for Public Health and the Environment) (submittedVersion)
Rivm (National Institute for Public Health and the Environment) (submittedVersion)
Rivm (National Institute for Public Health and the Environment) (submittedVersion, other-oa)
Radboud Repository (Radboud University) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: COVID-19 pandemic, SARS-CoV-2, serological assays, antibody detection, ELISA, receptor binding domain, virus-neutralizing antibodies, assay validation, diagnostic accuracy, exposure assessment, mass screening, disease severity
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Testing, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Humans, Luminescent Measurements, Neutralization Tests, Pneumonia, Viral, Sensitivity and Specificity, Serologic Tests, Coronavirus Infections, Clinical Laboratory Techniques, Antibodies, Neutralizing, High-Throughput Screening Assays, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks